Summary & Overview
HCPCS C9072: Injection, Immune Globulin (Asceniv) 500 mg
HCPCS Level II code C9072 denotes the administration of immune globulin (Asceniv), 500 mg. Its designation matters nationally as it standardizes reporting for a high-cost biologic injection used for passive immunization and immune support, influencing billing, coverage determinations, and utilization tracking across outpatient infusion settings. The code captures a specific branded formulation and dose, which affects payer coverage policies and prior authorization workflows.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how this HCPCS Level II code is used clinically and administratively, plus the typical sites of service where administrations occur. The publication summarizes benchmarking considerations, common billing and coding contexts, and relevant policy update themes that shape payer coverage and reimbursement for specialized immune globulin products. Practical insights cover documentation expectations tied to product-specific coding and the impact of dose-specific HCPCS assignment on billing precision.
Data not available in the input for some fields is noted where applicable.
Billing Code Overview
HCPCS Level II code C9072 represents Injection, immune globulin (asceniv), 500 mg. This code describes a biologic infusion or injection product used to provide passive immunity with a specified 500 mg dosage of the immune globulin formulation branded as Asceniv. The service type is an injection/infusion of immune globulin. The typical site of service is an outpatient infusion center, hospital outpatient department, or physician office where parenteral biologic therapies are administered.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with primary immunodeficiency or recurrent severe infections presents to an outpatient infusion center for administration of an immune globulin agent, specifically C9072 (Injection, immune globulin (asceniv), 500 mg). The clinical workflow begins with a physician or advanced practice provider evaluation confirming indication (e.g., common variable immunodeficiency, X-linked agammaglobulinemia, or specific antibody deficiency). Pre-infusion orders include verification of baseline vital signs, weight-based dose calculation, review of prior infusion reactions, and necessary laboratory studies (e.g., CBC, serum IgG level). The infusion nurse performs venous access placement, prepares the reconstituted product per manufacturer guidance, and programs the infusion pump with the prescribed rate. The infusion is initiated with close monitoring for infusion-related adverse events (headache, fever, hypotension, anaphylaxis). If a mild to moderate reaction occurs, infusion rate adjustments or temporary stoppage occur; severe reactions require emergency protocols and possible administration of epinephrine and transfer to higher level of care. Post-infusion documentation includes product lot number, expiration, total mg administered (multiples of 500 mg units), infusion start/end times, vital signs, and patient tolerance. Billing uses C9072 per 500 mg increment; appropriate HCPCS modifiers may be appended for unusual circumstances such as inpatient status, reduced services, or coordinator-designated modifier reporting. Typical site of service is an outpatient infusion center, hospital outpatient department, or skilled nursing facility when indicated. Typical patient scenario: ongoing maintenance therapy for primary immunodeficiency administered every 3–4 weeks, or an episodic high-dose regimen for immune modulation in select indications.
Coding Specifications
| Modifier |
|---|